The synergism of curcumin and oxaliplatin significantly suppressed CXCL8 (Interleukin-8), CXCL1 (Gro-α), and CXCL2 (Gro-β) in resistant CRC cells, resulting in the inhibition of the Akt/NF-κB signaling cascade [82]. The gene discussed is CXCL8; the disease is colorectal carcinoma.